CORPORATEPRESENTATION

F e b r u a r y 2 0 1 8

CSE: IN OTCQB: IMLFF

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements, including statements concerning anticipated clinical development activities, the potential benefits of product candidates and anticipated market opportunities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals. Readers are cautioned that the foregoing list is not exhaustive. For additional information with respect to risks and uncertainties, prospective investors should carefully review and consider the risk factors described under the section “Risk Factors” in the Company’s annual information form dated November 15, 2017, a copy of which is available on SEDAR at www.sedar.com and under the section “Risk Factors” in the short form prospectus. The company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

CSE:IN OTCQB:IMLFF2

3

OVERVIEW

InMed is a publicly listed, Vancouver-based biopharmaceutical company focused on identifying, developing and commercializing prescription cannabinoid drugs.

Core AssetsBioinformatics PlatformProprietary computer-based drug/disease targeting process

BiosynthesisProprietary manufacturing process for all 90+ cannabinoids

Drug Development PipelineCreating novel, non-THC, topically applied cannabinoid pharmaceuticals to treat diseases with high unmet medical needs, including:

➢ INM-750 for Epidermolysis Bullosa – An orphan disease characterized by extremely fragile skin. Potential global market revenues of ~US$1B per year.

➢ INM-085 for Glaucoma – A serious eye disease with a global market of >US$5B.

➢ INM-405 for Pain – Targeting topical administration. Total market >US$36B in 2017.

e

The endocannabinoid receptor system isa group of endogenous cannabinoidreceptors located in the mammalianbrain, throughout the central andperipheral nervous systems, and intissues and organs.

This system is predisposed tointeract with members ofthe cannabinoid drug family.

HEALING POWER OFCANNABINOIDS

4

90+ IndividualCannabinoid Compounds

EndocannabinoidReceptor System

80+ Cannabinoids

THC

CBD

+8

EACH HAS A POTENTIAL THERAPEUTIC ROLE INTHE HUMAN BODY

Cannabinoid Manufacturing:

Current Methods

5

Extraction from Plants ➢ Plant - Grow - Harvest - Extract - Purify process is

massively resource intensive, large carbon footprint, QA/QC issues

➢ Variations in cannabinoid content by strain➢ Expensive, takes months for a single production batch➢ Pesticide removal is challenging, may result in

import/export restrictions➢ Access to minor cannabinoids prohibitively expensive

Chemical Synthesis➢ Expensive, time consuming (weeks)➢ Excessive (toxic) waste➢ Problem of stereoisomers (structural integrity) may

affect efficacy/safety

6

Insert biosynthetic

cluster into vectorGenome engineering

of host

Sugar

ProductSimple process,

easy scale-up

Air

Straightforward purification

Microbe

Plant

CONFIDENTIAL

Industry-disruptive technology

BIOSYNTHESISA Smart Approach

Industry-disruptive technology

7

BIOSYNTHESIS

Advantages & Opportunities

ADVANTAGES

➢ Cost/time savings vs. plant-grow-harvest-extract-purify ➢ Enhanced production, purification, quality control vs.

agricultural approaches, including avoidance of any impurities (e.g. pesticides) in the final product

➢ Increased structural integrity vs. other chemical (synthetic) manufacturing methods; bio-identical to the plant compounds and no risk of random/inactive isomer production

➢ Access to minor cannabinoids that are currently economicallyunfeasible to extract via plant sources or synthesize chemically

OPPORTUNITIES

Cannabinoid / Cannabis Opportunities (Pharma, Nutraceuticals, ‘MMJ’, recreational)➢ Medical Marijuana market estimated to be $12B in 2016; will surpass $55B by 2025 ➢ US Market for medical CBD alone estimated at >$2B in 2020

Flavors and Fragrances (F&F)➢ Terpenoids / Terpenes found in cannabis, such as limonene, pinene, myrcene,

caryophylene can be made using biosynthesis➢ F&F industry is expected to surpass $37B by 2021

KEY TEAMFOR BIOSYNTHESISPROGRAM

Dr. Sazzad Hossain Chief Scientific Officer, PhD, M.Sc. Extensive experience in pharmaceutical development of natural compounds with Canada’s National Research Council. Also involved in the biosynthesis program there.

Ben Paterson, P.E. Mr. Paterson was previously a Senior Engineering Advisor with Eli Lilly and Company, where he spent 37 years, including 24 years in their biosynthesis division. His expertise includes processes definition, scale-up (pilot and commercial).

8

Dr. Vikram Yadav, Associate Professor, Department of Chemical & Biological Engineering at University of British Columbia (UBC). His research group specialize in metabolic & bioprocess engineering.

Dr. Protiva Roy, Research Scientist. PhD in Analytical Chemistry from Tokyo Institute of Technology, Japan and M.Scin Biochemistry from University of Dhaka, Bangladesh.

Dr. Sandip Pawar, Research Scientist. PhD in Bioprocess Technology from Institute of Chemical Technology, Mumbai and MSc on Pharmaceutical Technology from National Institute of Pharmaceutical Education & Research, India.

EPIDERMOLYSIS BULLOSA

INM-750

No approved treatments for EB

InMed’s lead product, INM-750 has many mechanisms-of-action in the skin to deliver symptomatic relief:

➢ accelerated wound healing ➢ pain reduction ➢ itch reduction➢ reduce inflammation➢ antimicrobial activity

INM-750 may re-establish the epidermal / dermal junction by upregulation of specific keratins in the skin, essentially reversing the disease.

~50K patients in N. America,Europe and Japan

9

>US$5B worldwide market~80M patients by 2020

GLAUCOMA:

INM-085

Serious Eye Disease Leading to Blindness

Dual Mechanism of Action➢ Reduces the intraocular pressure

(IOP) in the affected eyes; and➢ Provide neuroprotection for the retinal

ganglion cells (RGCs) and other optic nerve tissues in the affected eyes.

Proprietary Delivery System➢ INM-085 utilizes a 1x per day hydrogel

formulation to address the major issues of non-compliance (dosing frequency, side effects and adherence).

➢ Preclinical animal data showed enhanced penetration of cannabinoid molecules through the cornea and lens compared to control.

10

>US$36B worldwide marketfor all pain management drugs

PAIN MANAGEMENT:

INM-405

Local administration forPeripheral Pain Management

Temporomandibular Disorders (TMD)➢ Musculoskeletal and Neuromuscular (3)➢ TMJ, muscles and tissues➢ Mild to severe; 2x more women than men➢ 5-12% of total population➢ Treated with NSAIDS, anti-depressants

11

Trigeminal Neuralgia (TN)➢ “The Suicide Pain”➢ Severe, electric shock pain at root ➢ ~18,000 in USA (up to possibly 20K)➢ Treated with surgical intervention,

opioids, anti-convulsants, BOTOXTM

Pain of the Trigeminal Nerve

12

Robust & Diverse Opportunities

Therapeutic Area

Discovery / Disease Target

Selection

Target Validation (in vitro/vivo)

Formulation / Advanced Preclinical

ClinicalPh 1

Dermatology (Orphan)

- Epidermolysis Bullosa- Derm Disease 2- Derm Disease 3

**

2018*

Pain - Muscle Pain (TMD)

- Neuropathic Pain (TN)**

**

Ocular- Glaucoma * [Partner]

Fibrosis- COPD

TBD [Partner]

Neurodegenerative- Huntington’s

TBD [Partner]

Cancer- Breast Cancer

TBD [Partner]

INM-700 Series

INM-085

INM-400 Series

INM-300 Series

INM-100 Series

INM-200 Series

*Estimated timing dependent on, among other things, availability of capital.

13

Projects Funding Status

➢ Biosynthesis➢ Gene optimization for full library of cannabinoids➢ Scale-up to 50 L➢ Scale-up to 1000 L➢ Build Commercial Facility/Partner with CMO

✔

✔

✔

✘

➢ INM-750 in Epidermolysis Bullosa➢ Complete Formulation Development ➢ Conduct Toxicology studies ➢ File IND for initial human trial

➢ Initiate/complete Ph1 and Ph2

✔

✔

✔

✔ / TBD

➢ INM-085 for Glaucoma ➢ Finalize 1x day Hydrogel➢ Animal Studies / IOP Reduction➢ Commence Partnering Initiatives

✔

✔

✔

➢ INM-405 for Pain➢ Formulation Development➢ Additional TMD / TN studies in rats

✔

✔

Multiple Patent Filings Peer-reviewed publications of pre-clinical dataExpansion of Scientific Advisory BoardExpand Scientific and Executive Team

✔

✔

✔

✔

Priorities & Milestones

EXPERIENCED MANAGEMENT TEAM

Eric A. Adams CEO + President 25+ years’ experience in global biopharmaceutical leadership: business development, Sales, Marketing, M&A with enGene, QLT, Abbott Laboratories, Fresenius AG

Dr. Sazzad Hossain Chief Scientific Officer, PhD, M.Sc. 20+ years of academic/industry experience in drug discovery and product development at Xenon Pharmaceuticals, targeting pain, inflammation and cardiovascular diseases; and Canada’s National Research Council

Dr. Ado Muhammad Chief Medical Officer, MD, DPM, MFPM Former Associate Medical Director at GW Pharmaceuticals specializing in the development of cannabinoid-based prescription medicines

Alexandra Mancini Sr. Vice President, Clinical and Regulatory Affairs, M.Sc. 30 years’ global biopharmaceutical R&D experience with Sirius Genomics, Inex Pharmaceuticals, and QLT Inc.

14

Jeff Charpentier Chief Financial Officer + Corporate Secretary25+ years’ experience in biotech and technology companies including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems Inc.

Andrew Hull, VP of Global Alliances at Takeda Pharmaceuticals 30+ years’ pharma/biotech commercial leadership experience. Previously in various roles with Immunex and Abbott Labs. Two-term Chairman of Illinois Biotech Industry Organization.

Adam Cutler, CFO at Molecular Templates, Inc.20+ years of experience in Equity Research, Corporate Affairs and Finance, Investor Relations and Consulting. Previously Arbutus Biopharma, The Trout Group LLC, Credit Suisse, Canaccord Genuity, JMP Securities, BoA Securities, and The Frankel Group and E&Y Healthcare Consulting.

Martin Bott, VP Finance, Special Projects, Eli Lilly & Co30+years experience in Finance, Business Development and Operations in the global pharmaceutical industry. Previous roles include CFO of Diabetes and Global Manufacturing Units; stints in CH, D, UK.

Eric A. Adams, President + CEO, InMed Pharmaceuticals Inc.

BOARD OF DIRECTORS

15

William Garner, MD Chairman Founder, EGB Ventures Chairman/Founder of Race Oncology(ASX:RAC); Formerly Director +/- Executive at IGXBio; Invion Limited (ASX:IVX); Del Mar Pharma (NASDAQ: DMPI); Hoffmann LaRoche and healthcare merchant banking in NYC.

CAPITAL STRUCTURE

SymbolCSE: IN

OTCQB: IMLFF

Share I/O 1

Warrants 1

Options 1

Fully-Diluted 1

Market Capitalization 2

151.4 Million

17.4 Million

13.3 Million

182.1 Million 4

C$145.0 Million

1 As of January 18, 2018 2 As of February 02, 2018 on the CSE3 As of January 4, 2018 (Unaudited)4 Management, Founders & Insiders ~9% ownership

CSE:IN OTCQB:IMLFF

16

Cash 3 C$14.0 Million

INVESTMENT HIGHLIGHTSBroad portfolio of assets in

dermatology, ocular diseases, pain, additional indications and cannabinoid

biosynthesis

Positioned to achieve value-driving, near-term milestones:

➢ Biosynthesis of cannabinoids in advanced commercial scale-up in next 24 months

➢ Lead drug candidate in a disease with high unmet medical need; final formulation development, toxicology and Ph1-2 clinical trials targeted for

completion within 24 months

Experienced team capable of building value in biopharmaceuticals

CSE:IN OTCQB:IMLFF

17

THANK YOU!

InMed Pharmaceuticals Inc.

Eric A. Adams, President & CEOChris Bogart, Corporate Development & Investor Relations

#340-200 Granville Street Vancouver, BC Canada V6C 1S4 Tel: +1.604.669.7207 Fax: +1.604.683.2506www.inmedpharma.com

CSE:IN OTCQB:IMLFF

18